Old news but here it goes anyway: 40% of workforce cut across all functional areas, the company said June 5 of last year... 100 full-time equivalent employees left, 60 in sales and marketing positions. Cuts were cost-reduction measures that included in part a number of unspecified cost control initiatives to reduce OpEx and CapEx. Zogenix announced a need to conserve cash following slower-than-expected FDA review on its NDA for hydrocodone bitartrate ER (Zohydro ER) pills, an acetaminophen-free formulation of the opioid type painkiller. FDA delay followed an awkward 11–2 vote (one member abstained) on December 7 by FDA's Anesthetic/Analgesic Drug Advisory Committee, which recommended against approving Zohydro, citing its potential for drug abuse.
There are no replies in this thread yet. Be the first to post a reply below: